{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-078084","form_type":"8-K","ticker":null,"cik":"0001808865","company_name":"iTeos Therapeutics, Inc.","filed_at":"2025-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.812994+00:00","generated_at":"2026-05-20T08:31:52.582591+00:00","sec_items":["2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"iTeos Therapeutics to wind down operations after terminating belrestotug program and GSK collaboration","bullets":["Will wind down operations; expects severance charges of $21.8M-$24.7M and other program wind-down costs of $11.1M.","Exploring potential asset sales including EOS-984, EOS-215, and preclinical obesity program targeting ENT1.","Wind down substantially complete in Q3 2025; clinical development programs to wind down thereafter.","Amended employment agreements for CEO, COO, CMO with enhanced severance if terminated during change in control (excluding dissolution)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-078084","json":"https://secwatch.observer/filing/0000950170-25-078084.json","markdown":"https://secwatch.observer/filing/0000950170-25-078084.md","text":"https://secwatch.observer/filing/0000950170-25-078084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808865/000095017025078084/0000950170-25-078084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808865/000095017025078084/itos-20250527.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T08:31:52.582591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02d595b35f0741cca54441c66a9f3e7b8cb13106","claim":"iTeos Therapeutics, Inc. announced a restructuring with charges of $21.8 million to $24.7 million affecting Company-wide (clinical and operational activities).","evidence_excerpt":"The Company expects to incur charges in connection with the wind down consisting of (i) severance and other termination costs related to employees who would be terminated of approximately $21.8 million to $24.7 million","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808865/000095017025078084/0000950170-25-078084-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"$21.8 million to $24.7 million"},{"label":"Affected area","value":"Company-wide (clinical and operational activities)"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}